Ann: Appendix 4D and Half Year Financial Statements, page-3

I was holding LBT when it got FDA approval and the SP spiked 5-fold in a few days - v exciting. Admittedly, it mainly due to hype as the company didn't have recurring sales income at the time (and still doesn't). GSS is different in that it already has sales revenue growing nicely and plenty of cash. It feels a less risky stock, but still with plenty of upside as molecular diagnostics is such a growing field and FDA approval is still ahead. I'm not sure what sort of time frame's involved, often a share price will rise in anticipation of approval. I get the impression its maybe 1-2 years.